ZA202101671B - Imidazopyridinone compound - Google Patents

Imidazopyridinone compound

Info

Publication number
ZA202101671B
ZA202101671B ZA2021/01671A ZA202101671A ZA202101671B ZA 202101671 B ZA202101671 B ZA 202101671B ZA 2021/01671 A ZA2021/01671 A ZA 2021/01671A ZA 202101671 A ZA202101671 A ZA 202101671A ZA 202101671 B ZA202101671 B ZA 202101671B
Authority
ZA
South Africa
Prior art keywords
imidazopyridinone
compound
imidazopyridinone compound
Prior art date
Application number
ZA2021/01671A
Other languages
English (en)
Inventor
Moriyama Akihiro
Takigawa Yasushi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of ZA202101671B publication Critical patent/ZA202101671B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
ZA2021/01671A 2018-09-13 2021-03-11 Imidazopyridinone compound ZA202101671B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018171839 2018-09-13
PCT/JP2019/035792 WO2020054788A1 (ja) 2018-09-13 2019-09-12 イミダゾピリジノン化合物

Publications (1)

Publication Number Publication Date
ZA202101671B true ZA202101671B (en) 2022-07-27

Family

ID=69777067

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/01671A ZA202101671B (en) 2018-09-13 2021-03-11 Imidazopyridinone compound

Country Status (24)

Country Link
US (2) US12077531B2 (https=)
EP (1) EP3808747B1 (https=)
JP (1) JP7458987B2 (https=)
KR (1) KR102830577B1 (https=)
CN (1) CN112689637B (https=)
AR (1) AR116400A1 (https=)
AU (1) AU2019340173B2 (https=)
BR (1) BR112021004730A2 (https=)
CA (1) CA3106385A1 (https=)
DK (1) DK3808747T3 (https=)
ES (1) ES3016010T3 (https=)
FI (1) FI3808747T3 (https=)
HU (1) HUE069830T2 (https=)
IL (1) IL281391B2 (https=)
MX (1) MX2021003027A (https=)
MY (1) MY207239A (https=)
NZ (1) NZ773786A (https=)
PH (1) PH12021550512A1 (https=)
PL (1) PL3808747T3 (https=)
PT (1) PT3808747T (https=)
SG (1) SG11202102441VA (https=)
TW (1) TWI814903B (https=)
WO (1) WO2020054788A1 (https=)
ZA (1) ZA202101671B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414550B2 (ja) * 2020-01-23 2024-01-16 キッセイ薬品工業株式会社 (ヘテロ)アリールイミダゾロン化合物
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CA3169000A1 (en) * 2020-03-11 2021-09-16 Hideki Takeuchi Crystal of imidazopyridinone compound or salt thereof
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物
WO2025264818A1 (en) * 2024-06-20 2025-12-26 Raythera, Inc. Stat6 modulators and methods of uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
CA2344249A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
MXPA06000700A (es) * 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
EP1861377B1 (en) 2005-03-15 2010-12-29 Pfizer, Inc. Benzimidazolone derivatives as cb2 receptor ligands
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007015877A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20070142369A1 (en) 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
US20090298811A1 (en) 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CA2686485A1 (en) * 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2698071A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
CN101951777A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢呋喃并吡啶酮
EP2294066B9 (en) 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
EP2285375B1 (en) 2008-05-08 2013-04-10 Merck Sharp & Dohme Corp. spiroazaindole compounds as HIF propylhydroxylase inhibitors
EP2364313B1 (en) 2008-09-09 2014-01-08 Boehringer Ingelheim International GmbH Aza-benzimidazolone chymase inhibitors
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
JP2011037814A (ja) 2009-08-14 2011-02-24 Synstar Japan Co Ltd マラリア原虫疾患予防又は治療用の5−ヘテロ環置換イミノ−9−ジアルキルアミノベンゾ[a]フェノキサチン化合物又はその塩とアーテミシニン誘導体との組み合わせ
WO2011096490A1 (ja) 2010-02-04 2011-08-11 第一三共株式会社 イミダゾピリジン-2-オン誘導体
FR2967355B1 (fr) * 2010-11-17 2013-09-27 Jouvin Jean Luc Seringue dentaire securisee
WO2014181813A1 (ja) 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
EP3056975B1 (en) 2013-10-08 2020-08-12 Maxell, Ltd. Projection type image display device, manipulation detection device and projection type image display method
WO2015052675A1 (en) 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Substituted dihydro-benzimidazole compounds as ror gamma modulators
CN104926733B (zh) 2014-03-18 2019-05-10 北京韩美药品有限公司 作为RORγ调节剂的化合物
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
UA124090C2 (uk) * 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
RU2743126C9 (ru) 2016-08-22 2021-04-27 Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд. Ингибитор pde4
US10899758B2 (en) * 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
CA3087886A1 (en) * 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators

Also Published As

Publication number Publication date
IL281391A (en) 2021-04-29
IL281391B2 (en) 2025-04-01
AU2019340173A1 (en) 2021-04-08
US20240425504A1 (en) 2024-12-26
SG11202102441VA (en) 2021-04-29
MY207239A (en) 2025-02-08
JP7458987B2 (ja) 2024-04-01
CA3106385A1 (en) 2020-03-19
US12077531B2 (en) 2024-09-03
PT3808747T (pt) 2025-01-30
KR102830577B1 (ko) 2025-07-08
AU2019340173B2 (en) 2024-02-08
ES3016010T3 (en) 2025-05-08
IL281391B1 (en) 2024-12-01
EP3808747A1 (en) 2021-04-21
WO2020054788A1 (ja) 2020-03-19
NZ773786A (en) 2025-09-26
TW202024077A (zh) 2020-07-01
MX2021003027A (es) 2021-05-27
EP3808747B1 (en) 2024-12-18
CN112689637A (zh) 2021-04-20
EP3808747A4 (en) 2022-03-09
CN112689637B (zh) 2023-11-10
US20210206765A1 (en) 2021-07-08
FI3808747T3 (fi) 2025-02-07
AR116400A1 (es) 2021-05-05
KR20210057014A (ko) 2021-05-20
JPWO2020054788A1 (ja) 2021-08-30
TWI814903B (zh) 2023-09-11
HUE069830T2 (hu) 2025-04-28
BR112021004730A2 (pt) 2021-06-01
PL3808747T3 (pl) 2025-03-17
PH12021550512A1 (en) 2022-02-21
DK3808747T3 (da) 2025-02-03

Similar Documents

Publication Publication Date Title
GB201806578D0 (en) Novel compound
PL3827042T3 (pl) Związek wielo-azyrydynowy
GB201810092D0 (en) Compounds
GB201805174D0 (en) Compounds
GB201801355D0 (en) Compounds
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
ZA202101671B (en) Imidazopyridinone compound
GB201808093D0 (en) Compounds
GB201812382D0 (en) Compounds
GB201814151D0 (en) Compounds
GB201809102D0 (en) Compounds
GB201818649D0 (en) Compounds
GB201818651D0 (en) Compounds
GB201817083D0 (en) Compounds
GB201814167D0 (en) Compounds
GB201810071D0 (en) Compounds
GB201803340D0 (en) Compounds
GB201801130D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201819102D0 (en) Compounds
GB201818927D0 (en) Compounds
GB201818698D0 (en) Compounds
GB201818410D0 (en) Compounds
GB201817342D0 (en) Compounds